XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Revenue (Tables)

6 Months Ended

Jun. 30, 2024

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

The following table summarizes our revenue recognized in our consolidated condensed statements of operations:

			Three Months Ended June 30,												Six Months Ended June 30,
			2024						2023						2024						2023
Net product revenue			$	10,354.9					$	6,979.8					$	18,151.4					$	13,218.0
Collaboration and other revenue			947.9						1,332.3						1,919.4						2,054.1
Revenue			$	11,302.8					$	8,312.1					$	20,070.8					$	15,272.1

The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product for the three months ended June 30, 2024 and 2023:

			Three Months Ended June 30,
			2024												2023
			U.S.			Outside U.S.			Total						U.S.			Outside U.S.			Total
Cardiometabolic Health:
Mounjaro®			$	2,413.7		$	677.2		$	3,090.8					$	915.7		$	64.0		$	979.7
Trulicity®			876.7			368.9			1,245.6						1,371.3			441.2			1,812.5
Zepbound®			1,243.2			—			1,243.2						—			—			—
Jardiance(1)			428.9			340.7			769.6						386.1			282.2			668.3
Humalog® (2)			434.7			196.9			631.6						229.8			210.6			440.4
Humulin®			169.3			54.2			223.6						144.3			61.0			205.3
Basaglar® (3)			105.2			75.6			180.8						83.0			71.2			154.2
Baqsimi			3.3			9.0			12.4						606.2			7.7			613.9
Other cardiometabolic health			41.1			76.0			117.0						45.0			91.6			136.6
Total cardiometabolic health			5,716.1			1,798.5			7,514.6						3,781.4			1,229.5			5,010.9
Oncology:
Verzenio®			861.4			470.5			1,331.9						588.6			338.2			926.8
Cyramza®			116.1			132.8			248.9						115.0			145.3			260.3
Erbitux®			142.9			13.0			155.8						145.5			17.0			162.5
Tyvyt®			—			123.0			123.0						—			103.6			103.6
Other oncology			154.8			144.2			299.1						85.9			131.9			217.8
Total oncology			1,275.2			883.5			2,158.7						935.0			736.0			1,671.0
Immunology:
Taltz®			539.4			285.3			824.7						472.3			231.6			703.9
Olumiant®			44.5			183.2			227.7						50.8			168.1			218.9
Other immunology			15.9			14.1			30.0						—			5.7			5.7
Total immunology			599.8			482.6			1,082.4						523.1			405.4			928.5
Neuroscience:
Emgality®			137.6			54.4			192.0						118.8			50.5			169.3
Other neuroscience			54.3			93.2			147.5						42.1			175.8			217.9
Total neuroscience			191.9			147.6			339.5						160.9			226.3			387.2
Other:
Cialis®			7.5			80.2			87.7						9.2			106.4			115.6
Forteo®			31.5			38.5			69.9						97.4			50.6			148.0
Other			13.2			36.7			50.0						24.4			26.5			51.0
Total other			52.2			155.4			207.6						131.0			183.5			314.6
Revenue			$	7,835.2		$	3,467.5		$	11,302.8					$	5,531.4		$	2,780.7		$	8,312.1

Numbers may not add due to rounding.

(1) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR.

(2) Humalog revenue includes insulin lispro.

(3) Basaglar revenue includes Rezvoglar®.

The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product for the six months ended June 30, 2024 and 2023:

			Six Months Ended June 30,
			2024												2023
			U.S.			Outside U.S.			Total						U.S.			Outside U.S.			Total
Cardiometabolic Health:
Mounjaro			$	3,934.0		$	963.4		$	4,897.4					$	1,452.2		$	96.0		$	1,548.2
Trulicity			1,958.6			743.3			2,701.9						2,918.7			871.0			3,789.6
Zepbound			1,760.6			—			1,760.6						—			—			—
Jardiance(1)			797.1			659.0			1,456.1						715.6			530.2			1,245.8
Humalog(2)			773.0			397.3			1,170.3						501.4			400.0			901.4
Humulin			322.4			107.4			429.8						343.1			114.2			457.3
Basaglar(3)			188.4			149.9			338.3						218.4			145.2			363.5
Baqsimi			(6.9)			18.3			11.5						629.3			16.1			645.4
Other cardiometabolic health			78.9			163.0			241.7						77.7			172.2			250.1
Total cardiometabolic health			9,806.1			3,201.6			13,007.6						6,856.4			2,344.9			9,201.3
Oncology:
Verzenio			1,499.6			882.6			2,382.2						1,049.6			628.0			1,677.7
Cyramza			223.3			255.4			478.7						215.6			281.4			497.0
Erbitux			275.0			25.4			300.4						264.2			28.1			292.4
Tyvyt			—			239.7			239.7						—			164.6			164.6
Other oncology			275.6			292.0			567.7						159.0			236.5			395.3
Total oncology			2,273.5			1,695.1			3,968.7						1,688.4			1,338.6			3,027.0
Immunology:
Taltz			886.4			542.3			1,428.8						784.5			446.3			1,230.8
Olumiant			90.9			354.2			445.1						93.1			354.6			447.8
Other immunology			19.6			22.9			42.4						—			27.7			27.7
Total immunology			996.9			919.4			1,916.3						877.6			828.6			1,706.3
Neuroscience:
Emgality			262.7			155.1			417.8						227.5			96.1			323.6
Other neuroscience			92.4			218.4			310.8						77.9			346.2			424.1
Total neuroscience			355.1			373.5			728.6						305.4			442.3			747.7
Other:
Cialis			13.4			213.7			227.1						16.8			199.1			215.9
Forteo			53.2			78.0			131.2						168.0			102.3			270.3
Other			31.4			59.9			91.3						55.0			48.7			103.7
Total other			98.0			351.6			449.6						239.8			350.1			589.9
Revenue			$	13,529.6		$	6,541.2		$	20,070.8					$	9,967.6		$	5,304.6		$	15,272.1

Numbers may not add due to rounding.

(1) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR.

(2) Humalog revenue includes insulin lispro.

(3) Basaglar revenue includes Rezvoglar.

The following table summarizes revenue by geographical area:

			Three Months Ended June 30,												Six Months Ended June 30,
			2024						2023						2024						2023
Revenue(1):
U.S.			$	7,835.2					$	5,531.4					$	13,529.6					$	9,967.6
Europe			1,403.7						1,177.6						2,844.4						2,268.5
Japan			462.7						455.6						826.6						842.8
China			395.1						399.0						771.3						771.7
Other foreign countries			1,206.1						748.5						2,098.9						1,421.5
Revenue			$	11,302.8					$	8,312.1					$	20,070.8					$	15,272.1

Numbers may not add due to rounding.

(1) Revenue is attributed to the countries based on the location of the customer or other party.

Schedule of Amounts Recorded for Contract Liabilities

The following table summarizes contract liability balances:

			June 30, 2024						December 31, 2023
Contract liabilities			$	180.1					$	193.6

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration